Development and Characterization of Novel Nanoparticulate Gel Formulation for The State-of-the-Art Treatment in Topical Infection

Abstract

Mometasone is indicated in psoriasis and dermatitis, has poorwater solubility and low bioavailability causes skin irritation andhair follicle inflammation. To achieve a protective base for mometasone topically, an MF-PL complex-embedded NP-loaded gel was developed. MF-PL complex was prepared using the thin-film hydration method and was characterized for percentage yield,percentage drug complexation, and drug loading. Nanoparticles were incorporated into the gel base and subjected to yield, mometasone release, solution homogeneity, and particle size assessments.The objectives were to improve the drug release profile, loading capacity, permeation, and patient compliance, and to conduct stability studies. The crystalline form of mometasone furoate, melting point (219±1.0 to 225±1.0°C), and partition coefficient (4.19±0.385) confirmed its purity and lipophilic nature. DSC, UV-visible spectrophotometry, and FTIR analyses confirmed the purity and compatibility of the drug and excipients.The nanoparticle formulations exhibited homogeneous dispersion and physical stability, with formulation F.7A4 demonstrating excellent stability (zeta potential: -37.5 mV, hydrodynamic diameter: 191.60 nm). TEM and SEM confirmed the uniform shape, smooth surface texture, and nanometre-sized particles. The optimized MF-loaded phospholipid nanoparticle gel (F.7A4 (G-2)) exhibited a suitable pH (6.24±0.031), viscosity (2444±2.08 cps), high spreadability (7.23±0.021 g.cm/sec), and drug content (98.535%).Thestudy concluded that the MF-PL nanoparticle gel was successfully formulated and can be employed in the treatment of psoriasis and skin dermatitis with minimal side effects.